A low-emulsifier-containing diet led to a threefold increased likelihood of improvement in symptoms of Crohn’s disease ...

Patients with Crohn's disease and long-term ileostomy experience endoscopic recurrence, with ileal involvement and prior ...

In a major advance for patients with Crohn's disease, a new study led by researchers at Mount Sinai Health System found that ...

Treatment options for patients with moderately to severely active Crohn's disease have expanded in the past decade, with ...

Crohn's disease is a serious inflammatory bowel disease (IBD) that impacts millions worldwide. The disease is chronic and ...

In a major advance for patients with Crohn's disease, a new study led by researchers at Mount Sinai Health System found that ...

In a major advance for patients with Crohn’s disease, a new study led by researchers at Mount Sinai Health System found that guselkumab, a medication with a mechanism of action that is new to ...

There's one main way to treat inflammatory bowel disease (IBD): Control inflammation by whipping the immune system into shape, a process that can go haywire or fail to work. But what if the body could ...

Eli Lilly (LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on ...

Health technology assessment (HTA) agency NICE has published final draft guidance for IL-23 inhibitor Omvoh (mirikizumab), ...

Eli Lilly Canada Inc. (Lilly Canada) announced today that Health Canada has approved Omvoh® (mirikizumab) for CD, which will soon be available to patients in Canada. Omvoh® is an interleukin-23p19 ...